Forgot your password?
Forgot your username?
JOIN THE LPMA
FIND A PSYCHIATRIST
FOR THE PUBLIC
News, Information & Links
Continuing Medical Education
LPMA News & Updates
APA News & Updates
Please mark your calendars!
2014 Fall Meeting 04
2014 Fall Meeting 03
2014 Fall Meeting 02
2014 Fall Meeting 01
Frontpage Slideshow (version 2.0.0) - Copyright © 2006-2008 by JoomlaWorks
Find a Psychiatrist
Resources for the Public
Calendar of Events
A.G. Schneiderman Announces Settlement With Emblem Health For Wrongly Denying Mental Health And Substance Abuse Treatment For Thousands Of New York Members |
Click here to read the article
| The APA is now accepting abstract submissions for its
168th Annual Meeting to be held in Toronto, Ontario, Canada. May 16-21, 2015
. The theme of the meeting is
Psychiatry: Integrating Body and Mind, Heart and Soul.
The submission deadline is
Tuesday, September 9, 2014.
To submit an abstract, review the types of abstracts to be submitted, or learn more about the 2015 Annual Meeting please click
Psychiatric News Alert
The Voice of the
American Psychiatric Association
and the Psychiatric Community
Pipeline and Innovation for Psychotropic Drugs Are Limited, Study Finds
As development of drugs to treat psychiatric disorders lags behind that of drugs for other illnesses, a recent
Psychiatric Services in Advance
sheds light on why the pipeline for psychotropic medicines is nearly empty.
Researchers from Brandeis University and Truven Health Analytics led an investigation of the current state of psychotropic drugs in the pipeline and potential barriers that may keep these drugs from reaching distribution in the United States. Sifting through industry reports, company press releases, and the National Institutes of Health clinical trials website, the researchers gathered information on phase 3 trials for drugs being developed to treat major psychiatric disorders, including alcohol use disorder, schizophrenia, and depression. All studies involved adults aged 18 or older.
The analysis showed that the pipeline for psychotropic drug development—99 clinical trials were included—is limited, with little product innovation evident. Most of the examined drugs were a combination of existing of U.S. Food and Drug Administration-approved medicines or individually approved medicines that were being tested for new indications or delivery-system approaches (such as an injectable version that is similar to an approved oral form). Only three drugs differed substantially from existing drugs.
Among the barriers that hindered development of psychotropic drugs were incentives that encourage firms to focus on incremental innovation—such as a new version with fewer associated side effects—rather than taking risk on radically new...
MARK YOUR CALENDARS
Louisiana Psychiatric Medical Association &
Mississippi Psychiatric Association in Collaboration with the Louisiana & Mississippi Councils for Child & Adolescent Psychiatry
Join to Present their
February 27-28, 2015
Mississippi Gulf Coast
Please mark your calendars and stay tuned for more details.
LPMA • 9655 Perkins Rd. #C-152 • Baton Rouge, LA 70810 • PH: 225-761-3718 • FAX: 228-215-1256 •
Web Design by
Bruner and Company